Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
QuintilesIMS
Harvard Business School
Merck
AstraZeneca
Moodys
Accenture
Farmers Insurance
Dow
Cipla

Generated: January 18, 2018

DrugPatentWatch Database Preview

ASPIRIN Drug Profile

« Back to Dashboard

When do Aspirin patents expire, and what generic alternatives are available?

Aspirin is a drug marketed by Plx Pharma, Amneal Pharms, Barr, Impax Labs Inc, Par Pharm Inc, Sandoz Inc, and Zydus Pharms Usa Inc. and is included in seven NDAs. There are five patents protecting this drug.

This drug has thirty-two patent family members in eighteen countries.

The generic ingredient in ASPIRIN is aspirin; dipyridamole. There are twenty-one drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the aspirin; dipyridamole profile page.
Summary for ASPIRIN
Drug patent expirations by year for ASPIRIN

US Patents and Regulatory Information for ASPIRIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Plx Pharma ASPIRIN aspirin CAPSULE;ORAL 203697-001 Jan 14, 2013 OTC Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Plx Pharma ASPIRIN aspirin CAPSULE;ORAL 203697-001 Jan 14, 2013 OTC Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Plx Pharma ASPIRIN aspirin CAPSULE;ORAL 203697-001 Jan 14, 2013 OTC Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Impax Labs Inc ASPIRIN AND DIPYRIDAMOLE aspirin; dipyridamole CAPSULE, EXTENDED RELEASE;ORAL 206964-001 Jan 18, 2017 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sandoz Inc ASPIRIN AND DIPYRIDAMOLE aspirin; dipyridamole CAPSULE, EXTENDED RELEASE;ORAL 206739-001 Jan 18, 2017 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Plx Pharma ASPIRIN aspirin CAPSULE;ORAL 203697-001 Jan 14, 2013 OTC Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Plx Pharma ASPIRIN aspirin CAPSULE;ORAL 203697-001 Jan 14, 2013 OTC Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Amneal Pharms ASPIRIN AND DIPYRIDAMOLE aspirin; dipyridamole CAPSULE, EXTENDED RELEASE;ORAL 206392-001 Mar 8, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Zydus Pharms Usa Inc ASPIRIN AND DIPYRIDAMOLE aspirin; dipyridamole CAPSULE, EXTENDED RELEASE;ORAL 206753-001 Aug 29, 2017 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Par Pharm Inc ASPIRIN AND DIPYRIDAMOLE aspirin; dipyridamole CAPSULE, EXTENDED RELEASE;ORAL 207944-001 Jan 18, 2017 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for ASPIRIN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,730,884 pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same ➤ Subscribe
8,911,752 Methods of making compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity ➤ Subscribe
9,687,551 Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ASPIRIN

Supplementary Protection Certificates for ASPIRIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
12/048 Ireland ➤ Subscribe PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
2012000017 Germany ➤ Subscribe PRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Medtronic
US Department of Justice
QuintilesIMS
Queensland Health
McKesson
Cerilliant
Cantor Fitzgerald
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot